Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Aug 10:12:213-220.
doi: 10.2147/PTT.S323300. eCollection 2022.

Reducing the Risk of Developing Psoriatic Arthritis in Patients with Psoriasis

Paolo Gisondi  1 , Francesco Bellinato  1 , Martina Maurelli  1 , Davide Geat  1 , Alen Zabotti  2 , Dennis McGonagle  3 , Giampiero Girolomoni  1
Affiliations
Review

Reducing the Risk of Developing Psoriatic Arthritis in Patients with Psoriasis

Paolo Gisondi et al. Psoriasis (Auckl). .

Abstract

Psoriatic arthritis (PsA) is a heterogeneous chronic inflammatory arthritis associated with psoriasis, which may manifest with different domains such as dactylitis, enthesitis, synovitis and spondylitis. The estimated prevalence of PsA in patients with psoriasis ranges widely between 6% and 42%. In most cases, PsA is preceded by skin involvement by an average time of 7-8 years. In the complex patho-mechanisms involved in the transition from psoriasis to PsA, the gut and skin have been proposed as the sites of immune activation triggering or contributing to the development of PsA. In such a transition, a subclinical phase has been identified, characterized by enthesopathy where soluble biomarkers and imaging findings but no clinical symptoms are detectable. Recent studies have provided some evidence that timely treated psoriasis may reduce the risk of developing PsA.

Keywords: disease modification; early intervention; prevention; psoriasis; psoriatic arthritis; therapy.

PubMed Disclaimer

Conflict of interest statement

Gisondi P has been a consultant and/or speaker for Abbvie, Almirall, Amgen, Janssen, Leo-pharma, Eli Lilly, Novartis, Pierre Fabre, Sandoz, Sanofi, UCB. Girolomoni G served as consultant and/or speaker for AbbVie, Almirall, Amgen, Biogen, Boehringer Ingelheim, Bristol-Myers Squibb, Eli-Lilly, Leo Pharma, Novartis, Pfizer, Regeneron, Sanofi, Samsung and UCB. Zabotti A has been a consultant and/or speaker fo Abbvie, Amgen, Janssen, Eli Lilly, Novartis, UCB. D McGonagle has been a consultant and/or speaker for Abbvie, Amgen, Janssen, Eli Lilly, Novartis, UCB, Pfizer, BMS. The authors report no other conflicts of interest in this work.

Figures

Figure 1
Figure 1
Clinical and ultrasonographic findings of PsA showing Achilles tendinitis in a patient with plantar psoriasis.
See this image and copyright information in PMC

Comment in

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Dominguez-Rosado I, Moutinho V, DeMatteo RP, Kingham PT, D’Angelica M, Brennan MF. Outcomes of the memorial sloan kettering cancer center international general surgical oncology fellowship. J Am Coll Surg. 2016;222(5):961–966. doi:10.1016/j.jamcollsurg.2016.01.049 - DOI - PMC - PubMed
    1. Scotti L, Franchi M, Marchesoni A, Corrao G. Prevalence and incidence of psoriatic arthritis: a systematic review and meta-analysis. Semin Arthritis Rheum. 2018;48:28–34. - PubMed
    1. Alinaghi F, Calov M, Kristensen LE, et al. Prevalence of psoriatic arthritis in patients with psoriasis: a systematic review and meta-analysis of observational and clinical studies. J Am Acad Dermatol. 2019;80(1):251–265.e19. - PubMed
    1. Pennington SR, FitzGerald O. Early origins of psoriatic arthritis: clinical, genetic and molecular biomarkers of progression from psoriasis to psoriatic arthritis. Front Med. 2021;18(8):723944. - PMC - PubMed
    1. Ritchlin CT, Colbert RA, Gladman DD. Psoriatic arthritis. N Engl J Med. 2017;376(10):957–970. doi:10.1056/NEJMra1505557 - DOI - PubMed